查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1593753

全球发炎性肠道疾病（IBD）市场评估：按类型、药物类别、给药途径、分布、地区、机会、预测（2017-2031）

Inflammatory Bowel Disease Market Assessment, By Type, By Drug Class, By Route of Administration, By Distribution, By Region Opportunities and Forecast, 2017-2031F
出版日期: | 出版商: Market Xcel - Markets and Data | 英文 221 Pages | 商品交期: 3-5个工作天内

价格

全球发炎性肠道疾病（IBD）市场规模预计将从 2023 年的 220.7 亿美元增至 2031 年的 329.8 亿美元，预计 2024-2031 年复合年增长率为 5.15%。由于盛行率上升以及投资者和市场参与者兴趣的增长，预计发炎性肠道疾病（IBD）市场需求将在预测期内呈指数级增长。

根据 2024 年 6 月 17 日发表的系统性评价，欧洲溃疡性结肠炎和克隆氏症的盛行率分别约为每 10 万人中 24.3 人和 12.7 人。据通报，北美溃疡性结肠炎和克隆氏症的年发生率分别为每 10 万人中 19.2 例和 20.2 例。在亚洲，IBD 的盛行率为每 10 万人 0.5 至 3.4 人，显示该地区这种新兴疾病的动态变化。过去 10 至 15 年，韩国、日本、中国、香港和印度的发生率上升。这种成长在采用西方工业化生活方式的国家最为明显。

本报告研究和分析了全球发炎性肠道疾病 (IBD) 市场，提供市场规模和预测、市场动态和主要参与者趋势。

目录

第1章 专案范围与定义

第2章 研究方法

第3章 执行摘要

第4章全球发炎性肠道疾病（IBD）市场展望（2017-2031）

  • 市场规模分析与预测
    • 数量
  • 市占率分析与预测
    • 按类型
    • 按药物类别
    • 按给药途径
    • 按分布
    • 按地区
    • 市场占有率分析：按公司划分（金额）（前 5 名公司及其他 - 2023 年）
  • 市场地图分析（2023）
    • 按类型
    • 按药物类别
    • 按给药途径
    • 按分布
    • 按地区

第5章北美发炎性肠道疾病（IBD）市场展望（2017-2031）

  • 市场规模分析与预测
    • 数量
  • 市占率分析与预测
    • 按类型
    • 按药物类别
    • 按给药途径
    • 按分布
    • 分享：按国家/地区
  • 各国市场评估
    • 美国发炎性肠道疾病（IBD）市场展望（2017-2031）
    • 加拿大
    • 墨西哥

第6章欧洲发炎性肠道疾病（IBD）市场展望（2017-2031）

  • 德国
  • 法国
  • 义大利
  • 英国
  • 俄罗斯
  • 荷兰
  • 西班牙
  • 波兰

第7章亚太地区发炎性肠道疾病（IBD）市场展望（2017-2031）

  • 印度
  • 中国
  • 日本
  • 澳洲
  • 越南
  • 韩国
  • 印尼
  • 菲律宾

第8章南美洲发炎性肠道疾病（IBD）市场展望（2017-2031）

  • 巴西
  • 阿根廷

第9章中东和非洲发炎性肠道疾病（IBD）市场展望（2017-2031）

  • 沙乌地阿拉伯
  • 阿拉伯联合酋长国
  • 南非
  • 以色列

第10章 供需分析

第11章 进出口分析

第12章 价值链分析

第13章 波特五力分析

第14章 PESTLE分析

第15章价格分析

第16章 市场动态

  • 市场驱动力
  • 市场课题

第17章 市场趋势和发展

第18章 监理框架与创新

  • 临床试验
  • 监管审批

第19章 专利情况

第20章案例研究

第21章 竞争格局

  • 前5名市场领导者的竞争矩阵
  • 前5名企业SWOT分析
  • 前10名主要企业状况
    • AbbVie Inc.
    • Johnson & Johnson Services, Inc.
    • Pfizer Inc.
    • Merck & Co.
    • Novartis AG.
    • Amgen Inc.
    • Takeda Pharmaceutical Company Limited.
    • UCB S.A.
    • CELLTRION INC.
    • Bristol Myers Squibb

第22章 战略建议

第23章 关于我们公司、免责声明

Product Code: MX12265

Global inflammatory bowel disease market is projected to witness a CAGR of 5.15% during the forecast period 2024-2031, growing from USD 22.07 billion in 2023 to USD 32.98 billion in 2031. The market demand for Inflammatory Bowel Disease is anticipated to thrive drastically in the forecast years due to rising prevalence and the growing interest of investors and market players.

Inflammatory Bowel Disease is a chronic inflammatory condition of the gastrointestinal tract. It includes two types: Ulcerative colitis and Crohn's disease. Ulcerative colitis causes swelling and sores in the colon and rectum. Moreover, Crohn's disease affects the small intestine and large intestine, as well as the mouth, esophagus, stomach and anus. Common inflammatory bowel disease symptoms include abdominal pain, diarrhea (sometimes with blood), weight loss, rectal bleeding, fever, anemia, anxiety and depression. The diagnostic process for IBD involves multiple approaches. Clinicians typically start with a detailed medical history and physical examination. Some of the associated procedures include blood tests to evaluate anemia or inflammation, stool tests to exclude infection, and imaging studies such as CT scans or MRIs. The diagnosis is typically established through endoscopic procedures, namely colonoscopy, which permits direct visualization of the mucosal surfaces of the intestinal tract and tissue samples (biopsies) taken for further examination. For instance, as per a systematic review article published on 17 June 2024, reported that the incidence rate of Ulcerative Colitis and Crohn's Disease in the European region is approximately 24.3 and 12.7 per 100,000, respectively. The annual incidence rates for Ulcerative Colitis and Crohn's Disease in North America were reported at 19.2 and 20.2 per 100,000 individuals annually. The incidence of IBD in Asia ranges from 0.5 to 3.4 per 100,000 individuals, signifying the dynamic changing face of this emerging disease condition in the region. Incidence has risen over the past 10-15 years in Korea, Japan, China, Hong Kong, and India. The increase was more impressive in countries adopting a Western industrialized lifestyle.

Increase in the Prevalence of Inflammatory Bowel Disease

The increase in the prevalence of Ulcerative colitis and Crohn's disease is anticipated to fuel the growth of the inflammatory bowel disease market. Increasing inflammatory bowel disease is now emerging as a public health problem that is increasingly taking over industrialized nations. Several causes exist for the increase in this disease, with one significant cause being lifestyle changes: diets high on processed foods and low in fiber negatively impact health and gut health. In addition, the hygiene hypothesis provides an insight revealing that lower exposure to infections in the childhood period shows increased risk factors for autoimmune diseases, such as IBD. An urgent need to do further research into causes and treatments of IBD is a critical reason for the greater number of diagnosed cases. Public education campaigns are also needed towards communities about IBD for early detection and proper management of the disease. Considering that more people are living with the burden of IBD, managing this chronic illness needs a collective effort by providers, researchers, and policymakers to give better care and support to affected patients. For instance, in April 2024, Takeda Pharmaceutical Company Limited received approval from the U.S. Food and Drug Administration for ENTYVIO (vedolizumab) subcutaneous (SC) administration for the treatment in adults with moderately to severely active Crohn's disease (CD).

Advancements in the Treatment Options for Inflammatory Bowel Disease

Advancements in the treatment of inflammatory bowel disease include a wide approach to managing this chronic condition, such that patients are offered more effective and targeted therapies. Indeed, biologics, which target inflammatory pathways by specifically targeting cells, pathways, or molecules that contribute to inflammation, have revolutionized the management of this disease, from addressing underlying pathogenic mechanisms to the historical approach of symptom relief. Moreover, biologics like anti-TNF agents and integrin inhibitors have also proven useful in many patients' induction and maintenance of remission. New small molecules and JAK inhibitors are also emerging as additional alternatives in some cases. Personalized medicine has also advanced the ability of doctors to treat individual patients according to their individual genetic makeup and disease characteristics, thus offering a better chance for positive outcomes. Continued research and clinical trials are discovering additional new therapeutic targets, as well as new combination therapies, promising higher efficacy and safety. For instance, on 19 February 2024, Pfizer Inc. received approval from the European Commission (EC) granting marketing authorization for VELSIPITY (etrasimod) to treat patients 16 years of age and older with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or was intolerant to either conventional therapy or a biological agent. VELSIPITY is the first and only advanced oral ulcerative colitis treatment approved for use in patients 16 years of age.

Crohn's Disease Segment to Dominate the Inflammatory Bowel Disease Market

The Crohn's disease segment dominates the inflammatory bowel disease market due to the high prevalence and the specific need for treatment. Often, Crohn's disease affects any part of the gastrointestinal tract and generally causes more severe and varied symptoms than ulcerative colitis does, so its requirements are more complex, thus dictating a wide range of treatment options, including biologics, immunosuppressants, and emerging therapies tailored according to the needs of the individual patient. Other drivers for the growth of this segment include improved diagnosis techniques and increased awareness. Research and clinical studies in Crohn's disease continue to drive ongoing innovations and therapies that improve patient outcomes significantly, thus driving growth in the market. Also, with healthcare providers seeking more practical treatments for this chronic condition, the Crohn's disease market is poised to capture a greater share of the inflammatory bowel disease market. For instance, on 18 May 2023, AbbVie Inc. received approval from the U.S. Food and Drug Administration for RINVOQ (upadacitinib) to treat adults with moderate to severely active Crohn's disease. North America Dominates Inflammatory Bowel Disease Market

North America dominates the Inflammatory Bowel Disease (IBD) market, primarily driven by a combination of high prevalence rates, advanced healthcare infrastructure, and significant investment in research and development. The incidences of ulcerative colitis in North America range from 2.2 to 19.2 cases per 100,000 person-years, and Crohn's disease incidences range from 3.1 to 20.2 cases per 200,000 person-years. In the United States the prevalence of adult ulcerative colitis was 238 per 100,000 population and 201 per 100,000 population with data from a large study based on insurance claims. Inflammatory bowel disease is more prevalent in North America and Europe than in Asia or Africa. The region has a well-established healthcare system that makes it easier to administer new, advanced therapies such as biologics and emerging medications specifically designed to meet the needs of each patient. Well-organized awareness programs and support groups help facilitate earlier diagnosis and optimal management of the disease. For instance, on August 12, 2024, Celltrion USA, Inc. (Celltrion USA) received approval from the Food and Drug Administration for biosimilar adalimumab-aaty. Adalimumab-aaty is approved for the treatment of patients with rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease and Ulcerative colitis. The treatment for self-funded employer plans was available in the U.S. from Costco Specialty Pharmacy on October 1, 2023.

Future Market Scenario (2024-2031F)

The future market scenario seems promising for the inflammatory bowel disease market, influenced by factors that increase demand and investment in this market. The inflammatory bowel disease market is full of promise with the continuous advancement in research, technology, and options available for treatment. Moving into the future, with an increased understanding of the mechanisms driving IBD, more targeted therapies are emerging, such as biologics and small molecules targeting some of the pathways responsible for inflammation. In addition, the increasing incidence of IBD in emerging markets and globally will increase the patient population, which requires effective management systems. Improved diagnosis and early detection methods will ensure timely interventions, which will be beneficial to the patients and improve their quality of life. Other factors that will drive innovation in the field are stronger investment in research and more collaboration between pharmaceutical companies and academic institutions. For instance, on 4 October 2023, Sanofi and Teva Pharmaceuticals announced a collaboration to co-develop and co-commercialize asset TEV'574, currently in Phase 2b clinical trials for the treatment of Ulcerative Colitis and Crohn's Disease, the two types of inflammatory bowel disease.

Key Players Landscape and Outlook

The inflammatory bowel disease market is highly dynamic, with players like AbbVie Inc., Pfizer Inc., and many more. Market activity reported in recent years includes business agreements, collaborations, and regulatory approvals of market players' products. The market also fosters several smaller players, which operate through collaborations with other players to cater to a larger market.

On 8 July 2024, Eli Lilly and Company agreed to acquire Morphic Holding, Inc. to advance a first-in-class oral integrin treatment for serious chronic diseases, such as ulcerative colitis. Under the agreement, Lilly will acquire all outstanding shares of Morphic for approximately USD 3.2 billion.

On 28 June 2023, Eli Lilly and Company announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for mirikizumab (OMVOH) to treat moderately to severely active ulcerative colitis of adult patients.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Executive Summary

4. Global Inflammatory Bowel Disease Market Outlook, 2017-2031F

  • 4.1. Market Size Analysis & Forecast
    • 4.1.1. By Value
  • 4.2. Market Share Analysis & Forecast
    • 4.2.1. By Type
      • 4.2.1.1. Ulcerative Colitis
      • 4.2.1.2. Crohn's Disease
    • 4.2.2. By Drug Class
      • 4.2.2.1. Corticosteroids
      • 4.2.2.2. TNF Inhibitors
      • 4.2.2.3. Amino salicylates
      • 4.2.2.4. IL Inhibitors
      • 4.2.2.5. JAK Inhibitors
      • 4.2.2.6. Anti-integrin
      • 4.2.2.7. Others
    • 4.2.3. By Route of Administration
      • 4.2.3.1. Oral
      • 4.2.3.2. Injectable
    • 4.2.4. By Distribution
      • 4.2.4.1. Hospital Pharmacies
      • 4.2.4.2. Retail Pharmacies
      • 4.2.4.3. Online Pharmacies
      • 4.2.4.4. Others
    • 4.2.5. By Region
      • 4.2.5.1. North America
      • 4.2.5.2. Europe
      • 4.2.5.3. Asia-Pacific
      • 4.2.5.4. South America
      • 4.2.5.5. Middle East and Africa
    • 4.2.6. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2023)
  • 4.3. Market Map Analysis, 2023
    • 4.3.1. By Type
    • 4.3.2. By Drug Class
    • 4.3.3. By Route of Administration
    • 4.3.4. By Distribution
    • 4.3.5. By Region

5. North Inflammatory Bowel Disease Market Outlook, 2017-2031F*

  • 5.1. Market Size Analysis & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share Analysis & Forecast
    • 5.2.1. By Type
      • 5.2.1.1. Ulcerative Colitis
      • 5.2.1.2. Crohn's Disease
    • 5.2.2. By Drug Class
      • 5.2.2.1. Corticosteroids
      • 5.2.2.2. TNF Inhibitors
      • 5.2.2.3. Amino salicylates
      • 5.2.2.4. IL Inhibitors
      • 5.2.2.5. JAK Inhibitors
      • 5.2.2.6. Anti-integrin
      • 5.2.2.7. Others
    • 5.2.3. By Route of Administration
      • 5.2.3.1. Oral
      • 5.2.3.2. Injectable
    • 5.2.4. By Distribution
      • 5.2.4.1. Hospital Pharmacies
      • 5.2.4.2. Retail Pharmacies
      • 5.2.4.3. Online Pharmacies
      • 5.2.4.4. Others
    • 5.2.5. By Country Share
      • 5.2.5.1. United States
      • 5.2.5.2. Canada
      • 5.2.5.3. Mexico
  • 5.3. Country Market Assessment
    • 5.3.1. United States Inflammatory Bowel Disease Market Outlook, 2017-2031F*
      • 5.3.1.1. Market Size Analysis & Forecast
        • 5.3.1.1.1. By Value
      • 5.3.1.2. Market Share Analysis & Forecast
        • 5.3.1.2.1. By Type
          • 5.3.1.2.1.1. Ulcerative Colitis
          • 5.3.1.2.1.2. Crohn's Disease
        • 5.3.1.2.2. By Drug Class
          • 5.3.1.2.2.1. Corticosteroids
          • 5.3.1.2.2.2. TNF Inhibitors
          • 5.3.1.2.2.3. Amino salicylates
          • 5.3.1.2.2.4. IL Inhibitors
          • 5.3.1.2.2.5. JAK Inhibitors
          • 5.3.1.2.2.6. Anti-integrin
          • 5.3.1.2.2.7. Others
        • 5.3.1.2.3. By Route of Administration
          • 5.3.1.2.3.1. Oral
          • 5.3.1.2.3.2. Injectable
        • 5.3.1.2.4. By Distribution
          • 5.3.1.2.4.1. Hospitals Pharmacies
          • 5.3.1.2.4.2. Retail Pharmacies
          • 5.3.1.2.4.3. Online Pharmacies
          • 5.3.1.2.4.4. Others
    • 5.3.2. Canada
    • 5.3.3. Mexico

All segments will be provided for all regions and countries covered

6. Europe Inflammatory Bowel Disease Market Outlook, 2017-2031F

  • 6.1. Germany
  • 6.2. France
  • 6.3. Italy
  • 6.4. United Kingdom
  • 6.5. Russia
  • 6.6. Netherlands
  • 6.7. Spain
  • 6.8. Poland

7. Asia-Pacific Inflammatory Bowel Disease Market Outlook, 2017-2031F

  • 7.1. India
  • 7.2. China
  • 7.3. Japan
  • 7.4. Australia
  • 7.5. Vietnam
  • 7.6. South Korea
  • 7.7. Indonesia
  • 7.8. Philippines

8. South America Inflammatory Bowel Disease Market Outlook, 2017-2031F

  • 8.1. Brazil
  • 8.2. Argentina

9. Middle East and Africa Inflammatory Bowel Disease Market Outlook, 2017-2031F

  • 9.1. Saudi Arabia
  • 9.2. UAE
  • 9.3. South Africa
  • 9.4. Israel

10. Demand Supply Analysis

11. Import and Export Analysis

12. Value Chain Analysis

13. Porter's Five Forces Analysis

14. PESTLE Analysis

15. Pricing Analysis

16. Market Dynamics

  • 16.1. Market Drivers
  • 16.2. Market Challenges

17. Market Trends and Developments

18. Regulatory Framework and Innovation

  • 18.1. Clinical Trials
  • 18.2. Regulatory Approvals

19. Patent Landscape

20. Case Studies

21. Competitive Landscape

  • 21.1. Competition Matrix of Top 5 Market Leaders
  • 21.2. SWOT Analysis for Top 5 Players
  • 21.3. Key Players Landscape for Top 10 Market Players
    • 21.3.1. AbbVie Inc.
      • 21.3.1.1. Company Details
      • 21.3.1.2. Key Management Personnel
      • 21.3.1.3. Products and Services
      • 21.3.1.4. Financials (As Reported)
      • 21.3.1.5. Key Market Focus and Geographical Presence
      • 21.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisitions
    • 21.3.2. Johnson & Johnson Services, Inc.,
    • 21.3.3. Pfizer Inc.,
    • 21.3.4. Merck & Co.,
    • 21.3.5. Novartis AG.
    • 21.3.6. Amgen Inc.
    • 21.3.7. Takeda Pharmaceutical Company Limited.
    • 21.3.8. UCB S.A.
    • 21.3.9. CELLTRION INC.
    • 21.3.10. Bristol Myers Squibb.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

22. Strategic Recommendations

23. About Us and Disclaimer

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global Inflammatory Bowel Disease Market, By Value, In USD Billion, 2017-2031F
  • Figure 2. Global Inflammatory Bowel Disease Market Share (%), By Type, 2017-2031F
  • Figure 3. Global Inflammatory Bowel Disease Market Share (%), By Drug Class, 2017-2031F
  • Figure 4. Global Inflammatory Bowel Disease Market Share (%), By Route of Administration, 2017-2031F
  • Figure 5. Global Inflammatory Bowel Disease Market Share (%), By Distribution, 2017-2031F
  • Figure 6. Global Inflammatory Bowel Disease Market Share (%), By Region, 2017-2031F
  • Figure 7. North America Inflammatory Bowel Disease Market, By Value, In USD Billion, 2017-2031F
  • Figure 8. North America Inflammatory Bowel Disease Market Share (%), By Type, 2017-2031F
  • Figure 9. North America Inflammatory Bowel Disease Market Share (%), By Drug Class, 2017-2031F
  • Figure 10. North America Inflammatory Bowel Disease Market Share (%), By Route of Administration, 2017-2031F
  • Figure 11. North America Inflammatory Bowel Disease Market Share (%), By Distribution, 2017-2031F
  • Figure 12. North America Inflammatory Bowel Disease Market Share (%), By Country, 2017-2031F
  • Figure 13. United States Inflammatory Bowel Disease Market, By Value, In USD Billion, 2017-2031F
  • Figure 14. United States Inflammatory Bowel Disease Market Share (%), By Type, 2017-2031F
  • Figure 15. United States Inflammatory Bowel Disease Market Share (%), By Drug Class, 2017-2031F
  • Figure 16. United States Inflammatory Bowel Disease Market Share (%), By Route of Administration, 2017-2031F
  • Figure 17. United States Inflammatory Bowel Disease Market Share (%), By Distribution, 2017-2031F
  • Figure 18. Canada Inflammatory Bowel Disease Market, By Value, In USD Billion, 2017-2031F
  • Figure 19. Canada Inflammatory Bowel Disease Market Share (%), By Type, 2017-2031F
  • Figure 20. Canada Inflammatory Bowel Disease Market Share (%), By Drug Class, 2017-2031F
  • Figure 21. Canada Inflammatory Bowel Disease Market Share (%), By Route of Administration, 2017-2031F
  • Figure 22. Canada Inflammatory Bowel Disease Market Share (%), By Distribution, 2017-2031F
  • Figure 23. Mexico Inflammatory Bowel Disease Market, By Value, In USD Billion, 2017-2031F
  • Figure 24. Mexico Inflammatory Bowel Disease Market Share (%), By Type, 2017-2031F
  • Figure 25. Mexico Inflammatory Bowel Disease Market Share (%), By Drug Class, 2017-2031F
  • Figure 26. Mexico Inflammatory Bowel Disease Market Share (%), By Route of Administration, 2017-2031F
  • Figure 27. Mexico Inflammatory Bowel Disease Market Share (%), By Distribution, 2017-2031F
  • Figure 28. Europe Inflammatory Bowel Disease Market, By Value, In USD Billion, 2017-2031F
  • Figure 29. Europe Inflammatory Bowel Disease Market Share (%), By Type, 2017-2031F
  • Figure 30. Europe Inflammatory Bowel Disease Market Share (%), By Drug Class, 2017-2031F
  • Figure 31. Europe Inflammatory Bowel Disease Market Share (%), By Route of Administration, 2017-2031F
  • Figure 32. Europe Inflammatory Bowel Disease Market Share (%), By Distribution, 2017-2031F
  • Figure 33. Europe Inflammatory Bowel Disease Market Share (%), By Country, 2017-2031F
  • Figure 34. Germany Inflammatory Bowel Disease Market, By Value, In USD Billion, 2017-2031F
  • Figure 35. Germany Inflammatory Bowel Disease Market Share (%), By Type, 2017-2031F
  • Figure 36. Germany Inflammatory Bowel Disease Market Share (%), By Drug Class, 2017-2031F
  • Figure 37. Germany Inflammatory Bowel Disease Market Share (%), By Route of Administration, 2017-2031F
  • Figure 38. Germany Inflammatory Bowel Disease Market Share (%), By Distribution, 2017-2031F
  • Figure 39. France Inflammatory Bowel Disease Market, By Value, In USD Billion, 2017-2031F
  • Figure 40. France Inflammatory Bowel Disease Market Share (%), By Type, 2017-2031F
  • Figure 41. France Inflammatory Bowel Disease Market Share (%), By Drug Class, 2017-2031F
  • Figure 42. France Inflammatory Bowel Disease Market Share (%), By Route of Administration, 2017-2031F
  • Figure 43. France Inflammatory Bowel Disease Market Share (%), By Distribution, 2017-2031F
  • Figure 44. Italy Inflammatory Bowel Disease Market, By Value, In USD Billion, 2017-2031F
  • Figure 45. Italy Inflammatory Bowel Disease Market Share (%), By Type, 2017-2031F
  • Figure 46. Italy Inflammatory Bowel Disease Market Share (%), By Drug Class, 2017-2031F
  • Figure 47. Italy Inflammatory Bowel Disease Market Share (%), By Route of Administration, 2017-2031F
  • Figure 48. Italy Inflammatory Bowel Disease Market Share (%), By Distribution, 2017-2031F
  • Figure 49. United Kingdom Inflammatory Bowel Disease Market, By Value, In USD Billion, 2017-2031F
  • Figure 50. United Kingdom Inflammatory Bowel Disease Market Share (%), By Type, 2017-2031F
  • Figure 51. United Kingdom Inflammatory Bowel Disease Market Share (%), By Drug Class, 2017-2031F
  • Figure 52. United Kingdom Inflammatory Bowel Disease Market Share (%), By Route of Administration, 2017-2031F
  • Figure 53. United Kingdom Inflammatory Bowel Disease Market Share (%), By Distribution, 2017-2031F
  • Figure 54. Russia Inflammatory Bowel Disease Market, By Value, In USD Billion, 2017-2031F
  • Figure 55. Russia Inflammatory Bowel Disease Market Share (%), By Type, 2017-2031F
  • Figure 56. Russia Inflammatory Bowel Disease Market Share (%), By Drug Class, 2017-2031F
  • Figure 57. Russia Inflammatory Bowel Disease Market Share (%), By Route of Administration, 2017-2031F
  • Figure 58. Russia Inflammatory Bowel Disease Market Share (%), By Distribution, 2017-2031F
  • Figure 59. Netherlands Inflammatory Bowel Disease Market, By Value, In USD Billion, 2017-2031F
  • Figure 60. Netherlands Inflammatory Bowel Disease Market Share (%), By Type, 2017-2031F
  • Figure 61. Netherlands Inflammatory Bowel Disease Market Share (%), By Drug Class, 2017-2031F
  • Figure 62. Netherlands Inflammatory Bowel Disease Market Share (%), By Route of Administration, 2017-2031F
  • Figure 63. Netherlands Inflammatory Bowel Disease Market Share (%), By Distribution, 2017-2031F
  • Figure 64. Spain Inflammatory Bowel Disease Market, By Value, In USD Billion, 2017-2031F
  • Figure 65. Spain Inflammatory Bowel Disease Market Share (%), By Type, 2017-2031F
  • Figure 66. Spain Inflammatory Bowel Disease Market Share (%), By Drug Class, 2017-2031F
  • Figure 67. Spain Inflammatory Bowel Disease Market Share (%), By Route of Administration, 2017-2031F
  • Figure 68. Spain Inflammatory Bowel Disease Market Share (%), By Distribution, 2017-2031F
  • Figure 69. Turkey Inflammatory Bowel Disease Market, By Value, In USD Billion, 2017-2031F
  • Figure 70. Turkey Inflammatory Bowel Disease Market Share (%), By Type, 2017-2031F
  • Figure 71. Turkey Inflammatory Bowel Disease Market Share (%), By Drug Class, 2017-2031F
  • Figure 72. Turkey Inflammatory Bowel Disease Market Share (%), By Route of Administration, 2017-2031F
  • Figure 73. Turkey Inflammatory Bowel Disease Market Share (%), By Distribution, 2017-2031F
  • Figure 74. Poland Inflammatory Bowel Disease Market, By Value, In USD Billion, 2017-2031F
  • Figure 75. Poland Inflammatory Bowel Disease Market Share (%), By Type, 2017-2031F
  • Figure 76. Poland Inflammatory Bowel Disease Market Share (%), By Drug Class, 2017-2031F
  • Figure 77. Poland Inflammatory Bowel Disease Market Share (%), By Route of Administration, 2017-2031F
  • Figure 78. Poland Inflammatory Bowel Disease Market Share (%), By Distribution, 2017-2031F
  • Figure 79. South America Inflammatory Bowel Disease Market, By Value, In USD Billion, 2017-2031F
  • Figure 80. South America Inflammatory Bowel Disease Market Share (%), By Type, 2017-2031F
  • Figure 81. South America Inflammatory Bowel Disease Market Share (%), By Drug Class, 2017-2031F
  • Figure 82. South America Inflammatory Bowel Disease Market Share (%), By Route of Administration, 2017-2031F
  • Figure 83. South America Inflammatory Bowel Disease Market Share (%), By Distribution, 2017-2031F
  • Figure 84. South America Inflammatory Bowel Disease Market Share (%), By Country, 2017-2031F
  • Figure 85. Brazil Inflammatory Bowel Disease Market, By Value, In USD Billion, 2017-2031F
  • Figure 86. Brazil Inflammatory Bowel Disease Market Share (%), By Type, 2017-2031F
  • Figure 87. Brazil Inflammatory Bowel Disease Market Share (%), By Drug Class, 2017-2031F
  • Figure 88. Brazil Inflammatory Bowel Disease Market Share (%), By Route of Administration, 2017-2031F
  • Figure 89. Brazil Inflammatory Bowel Disease Market Share (%), By Distribution, 2017-2031F
  • Figure 90. Argentina Inflammatory Bowel Disease Market, By Value, In USD Billion, 2017-2031F
  • Figure 91. Argentina Inflammatory Bowel Disease Market Share (%), By Type, 2017-2031F
  • Figure 92. Argentina Inflammatory Bowel Disease Market Share (%), By Drug Class, 2017-2031F
  • Figure 93. Argentina Inflammatory Bowel Disease Market Share (%), By Route of Administration, 2017-2031F
  • Figure 94. Argentina Inflammatory Bowel Disease Market Share (%), By Distribution, 2017-2031F
  • Figure 95. Asia-Pacific Inflammatory Bowel Disease Market, By Value, In USD Billion, 2017-2031F
  • Figure 96. Asia-Pacific Inflammatory Bowel Disease Market Share (%), By Type, 2017-2031F
  • Figure 97. Asia-Pacific Inflammatory Bowel Disease Market Share (%), By Drug Class, 2017-2031F
  • Figure 98. Asia-Pacific Inflammatory Bowel Disease Market Share (%), By Route of Administration, 2017-2031F
  • Figure 99. Asia-Pacific Inflammatory Bowel Disease Market Share (%), By Distribution, 2017-2031F
  • Figure 100. Asia-Pacific Inflammatory Bowel Disease Market Share (%), By Country, 2017-2031F
  • Figure 101. India Inflammatory Bowel Disease Market, By Value, In USD Billion, 2017-2031F
  • Figure 102. India Inflammatory Bowel Disease Market Share (%), By Type, 2017-2031F
  • Figure 103. India Inflammatory Bowel Disease Market Share (%), By Drug Class, 2017-2031F
  • Figure 104. India Inflammatory Bowel Disease Market Share (%), By Route of Administration, 2017-2031F
  • Figure 105. India Inflammatory Bowel Disease Market Share (%), By Distribution, 2017-2031F
  • Figure 106. China Inflammatory Bowel Disease Market, By Value, In USD Billion, 2017-2031F
  • Figure 107. China Inflammatory Bowel Disease Market Share (%), By Type, 2017-2031F
  • Figure 108. China Inflammatory Bowel Disease Market Share (%), By Drug Class, 2017-2031F
  • Figure 109. China Inflammatory Bowel Disease Market Share (%), By Route of Administration, 2017-2031F
  • Figure 110. China Inflammatory Bowel Disease Market Share (%), By Distribution, 2017-2031F
  • Figure 111. Japan Inflammatory Bowel Disease Market, By Value, In USD Billion, 2017-2031F
  • Figure 112. Japan Inflammatory Bowel Disease Market Share (%), By Type, 2017-2031F
  • Figure 113. Japan Inflammatory Bowel Disease Market Share (%), By Drug Class, 2017-2031F
  • Figure 114. Japan Inflammatory Bowel Disease Market Share (%), By Route of Administration, 2017-2031F
  • Figure 115. Japan Inflammatory Bowel Disease Market Share (%), By Distribution, 2017-2031F
  • Figure 116. Australia Inflammatory Bowel Disease Market, By Value, In USD Billion, 2017-2031F
  • Figure 117. Australia Inflammatory Bowel Disease Market Share (%), By Type, 2017-2031F
  • Figure 118. Australia Inflammatory Bowel Disease Market Share (%), By Drug Class, 2017-2031F
  • Figure 119. Australia Inflammatory Bowel Disease Market Share (%), By Route of Administration, 2017-2031F
  • Figure 120. Australia Inflammatory Bowel Disease Market Share (%), By Distribution, 2017-2031F
  • Figure 121. Vietnam Inflammatory Bowel Disease Market, By Value, In USD Billion, 2017-2031F
  • Figure 122. Vietnam Inflammatory Bowel Disease Market Share (%), By Type, 2017-2031F
  • Figure 123. Vietnam Inflammatory Bowel Disease Market Share (%), By Drug Class, 2017-2031F
  • Figure 124. Vietnam Inflammatory Bowel Disease Market Share (%), By Route of Administration, 2017-2031F
  • Figure 125. Vietnam Inflammatory Bowel Disease Market Share (%), By Distribution, 2017-2031F
  • Figure 126. South Korea Inflammatory Bowel Disease Market, By Value, In USD Billion, 2017-2031F
  • Figure 127. South Korea Inflammatory Bowel Disease Market Share (%), By Type, 2017-2031F
  • Figure 128. South Korea Inflammatory Bowel Disease Market Share (%), By Drug Class, 2017-2031F
  • Figure 129. South Korea Inflammatory Bowel Disease Market Share (%), By Route of Administration, 2017-2031F
  • Figure 130. South Korea Inflammatory Bowel Disease Market Share (%), By Distribution, 2017-2031F
  • Figure 131. Indonesia Inflammatory Bowel Disease Market, By Value, In USD Billion, 2017-2031F
  • Figure 132. Indonesia Inflammatory Bowel Disease Market Share (%), By Type, 2017-2031F
  • Figure 133. Indonesia Inflammatory Bowel Disease Market Share (%), By Drug Class, 2017-2031F
  • Figure 134. Indonesia Inflammatory Bowel Disease Market Share (%), By Route of Administration, 2017-2031F
  • Figure 135. Indonesia Inflammatory Bowel Disease Market Share (%), By Distribution, 2017-2031F
  • Figure 136. Philippines Inflammatory Bowel Disease Market, By Value, In USD Billion, 2017-2031F
  • Figure 137. Philippines Inflammatory Bowel Disease Market Share (%), By Type, 2017-2031F
  • Figure 138. Philippines Inflammatory Bowel Disease Market Share (%), By Drug Class, 2017-2031F
  • Figure 139. Philippines Inflammatory Bowel Disease Market Share (%), By Route of Administration, 2017-2031F
  • Figure 140. Philippines Inflammatory Bowel Disease Market Share (%), By Distribution, 2017-2031F
  • Figure 141. Middle East & Africa Inflammatory Bowel Disease Market, By Value, In USD Billion, 2017-2031F
  • Figure 142. Middle East & Africa Inflammatory Bowel Disease Market Share (%), By Type, 2017-2031F
  • Figure 143. Middle East & Africa Inflammatory Bowel Disease Market Share (%), By Drug Class, 2017-2031F
  • Figure 144. Middle East & Africa Inflammatory Bowel Disease Market Share (%), By Route of Administration, 2017-2031F
  • Figure 145. Middle East & Africa Inflammatory Bowel Disease Market Share (%), By Distribution, 2017-2031F
  • Figure 146. Middle East & Africa Inflammatory Bowel Disease Market Share (%), By Country, 2017-2031F
  • Figure 147. Saudi Arabia Inflammatory Bowel Disease Market, By Value, In USD Billion, 2017-2031F
  • Figure 148. Saudi Arabia Inflammatory Bowel Disease Market Share (%), By Type, 2017-2031F
  • Figure 149. Saudi Arabia Inflammatory Bowel Disease Market Share (%), By Drug Class, 2017-2031F
  • Figure 150. Saudi Arabia Inflammatory Bowel Disease Market Share (%), By Route of Administration, 2017-2031F
  • Figure 151. Saudi Arabia Inflammatory Bowel Disease Market Share (%), By Distribution, 2017-2031F
  • Figure 152. UAE Inflammatory Bowel Disease Market, By Value, In USD Billion, 2017-2031F
  • Figure 153. UAE Inflammatory Bowel Disease Market Share (%), By Type, 2017-2031F
  • Figure 154. UAE Inflammatory Bowel Disease Market Share (%), By Drug Class, 2017-2031F
  • Figure 155. UAE Inflammatory Bowel Disease Market Share (%), By Route of Administration, 2017-2031F
  • Figure 156. UAE Inflammatory Bowel Disease Market Share (%), By Distribution, 2017-2031F
  • Figure 157. South Africa Inflammatory Bowel Disease Market, By Value, In USD Billion, 2017-2031F
  • Figure 158. South Africa Inflammatory Bowel Disease Market Share (%), By Type, 2017-2031F
  • Figure 159. South Africa Inflammatory Bowel Disease Market Share (%), By Drug Class, 2017-2031F
  • Figure 160. South Africa Inflammatory Bowel Disease Market Share (%), By Route of Administration, 2017-2031F
  • Figure 161. South Africa Inflammatory Bowel Disease Market Share (%), By Distribution, 2017-2031F
  • Figure 162. By Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 163. By Drug Class Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 164. By Route of Administration Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 165. By Distribution Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 166. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023